Loss of PTPRS function through mutation or deletion has been shown to increase TKI resistance in multiple human preclinical cancer models and has been linked with worse overall survival and more rapid disease progression in patients with EGFR-driven lung cancer29–31. Here, EGFR is linked to cancer.